Based on ratings from 0 stock analysts, the Surrozen, Inc. stock price is expected to increase by 293.79% in 12 months. This is calculated by using the average 12-month stock price forecast for Surrozen, Inc.. The lowest target is $33 and the highest is $33. Please note analyst price targets are not guaranteed and could be missed completely.
Surrozen, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Surrozen, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of SRZN.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Eric Joseph JP Morgan | Underweight | Downgrade | Nov 29, 2022 | |
Yatin Suneja Guggenheim | Neutral | Downgrade | Nov 18, 2022 | |
Tazeen Ahmad B of A Securities | Underperform | $1 | Downgrade | Nov 17, 2022 |
Eric Joseph JP Morgan | Neutral | Initiates | Oct 17, 2022 | |
Tazeen Ahmad B of A Securities | Neutral | $5 | Downgrade | May 27, 2022 |
B of A Securities | Buy | Initiates | Oct 11, 2021 | |
Guggenheim | Buy | Initiates | Sep 15, 2021 | |
Stifel | Buy | Initiates | Sep 7, 2021 |
When did it IPO
N/A
Staff Count
42
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Craig C. Parker M.B.A.
Market Cap
$30.1M
In 2023, SRZN generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that SRZN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.